ArticleBMC medical imaging2025
CT-assessed pectoralis major muscle measurements as risk factors for low neoadjuvant chemotherapy efficacy in osteosarcoma: a retrospective study.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a nomogram for predicting pulmonary embolism recurrence using muscle and fat parameters.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNeoadjuvant chemotherapy (NAC) response in terms of tumor necrosis for osteosarcoma is of clinical significance for subsequent treatment, CT-acquired parameters indicating sarcopenia were reported to be the risk factors of low NAC efficacy in a variety of malignant tumors, yet the association between chest CT-derived pectoralis major muscle measurements and tumor necrosis of osteosarcoma have not been revealed.
methodsThe pectoralis major muscle area, normalized pectoralis major muscle index (PMI) and CT attenuation acquired from preoperative chest CT as well as clinical data of 131 osteosarcoma patients were retrospectively analyzed and compared between favorable NAC response (tumor necrosis ≥ 90%) and poor NAC response group (tumor necrosis < 90%). For the evaluation of interobserver reproducibility, interclass correlation coefficient (ICC) with 95% confidence interval (CI) was used. The receiver operating characteristic (ROC) analysis was performed to determine the efficiency of each measurement and to calculate the optimal cut-off values of significant parameters. Multivariable binary logistic regression analysis was performed to determine the risk factors of low NAC efficacy.
resultsA total of 79 lesions from 78 patients were eligible for this study (mean age, 17.6 ± 0.9 years; 45 male), 34 lesions constituted the favorable response (FR) group and 45 lesions constituted the poor response (PR) group. Pectoralis major muscle measurements were significantly higher in FR group than in PR group (muscle area, 11.56 ± 4.48 VS 9.42 ± 3.57, P = 0.021; PMI, 7.32 ± 2.23 VS 5.64 ± 1.54, P < 0.001; CT attenuation, 38.78 ± 8.44 VS 31.96 ± 11.37, P = 0.004). Excellent interobserver agreement was found in these parameters with ICC values ranging 0.925-0.944. In ROC analysis, PMI showed an area under curve (AUC) of 0.727, 95% CI: 0.612, 0.842, the threshold value for differentiating FR from PR was 7.147. PMI were risk factors of low NAC efficacy with the P value of 0.007.
conclusionsChest CT-accessed pectoralis major muscle area, PMI and CT attenuation were significantly correlated with tumor necrosis in osteosarcoma, these can be potentially helpful imaging auxiliary biomarkers for predicting NAC response of osteosarcoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.